Open Access

ZW10 interacting kinetochore protein may serve as a prognostic biomarker for human breast cancer: An integrated bioinformatics analysis

  • Authors:
    • Han‑Ning Li
    • Wei‑Hong Zheng
    • Ya‑Ying Du
    • Ge Wang
    • Meng‑Lu Dong
    • Zhi‑Fang Yang
    • Xing‑Rui Li
  • View Affiliations

  • Published online on: January 24, 2020     https://doi.org/10.3892/ol.2020.11353
  • Pages: 2163-2174
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

ZW10 interacting kinetochore protein (ZWINT) is an essential component for the mitotic spindle checkpoint and has been reported to be upregulated in numerous types of human cancer. Nonetheless, its role in breast cancer (BC) remains unclear. Herein, it was demonstrated that the expression of ZWINT was significantly higher in BC than in normal breast tissues, on the basis of integrated analysis of bioinformatics studies, cancer database analyses and immunohistochemical detection. Elevated ZWINT levels were associated with a number of clinicopathological characteristics in patients with BC. These characteristics include: i) Positive human epidermal growth factor receptor 2 expression; ii) triple‑negative BC; iii) younger age; iv) basal‑like subtype; and v) greater Scarff‑Bloom‑Richardson grades. Additionally, prognostic analysis indicated that shorter relapse‑free survival, overall survival and metastatic relapse‑free survival may be associated with high ZWINT expression. A total of 16 pathways associated with high ZWINT expression, including Myc targets V1/2, DNA repair and mitotic spindle pathways, were identified using Gene Set Enrichment Analysis. In addition, a positive correlation between cyclin‑dependent kinase 1 (CDK1) and ZWINT mRNA expression was identified by co‑expression analysis. The present study suggested that ZWINT may serve as an effective prognostic biomarker for BC. In addition, ZWINT may be implicated in the CDK1‑mediated initiation and progression of BC. However, further research is required to understand the role of ZWINT in BC.

Introduction

Breast cancer (BC) is a common malignancy among women. According to recent cancer statistics, ~2.1 million women worldwide were diagnosed with BC and ~627,000 individuals died from the condition in 2018 (1). The prognosis of patients with BC has substantially improved in recent decades owing to the rapid advancement in diagnostic methods and individualized treatments. Nevertheless, this disease poses a severe threat to female health (2,3). Routine diagnosis and treatment are rarely effective in certain patients due to the intratumor heterogeneity of BC. Therefore, the identification of novel and more reliable molecular biomarkers for the prediction of outcomes and targeted treatments for BC is crucial.

As part of the kinetochore complex, ZW10 interacting kinetochore protein (ZWINT) is required for the mitotic spindle checkpoint (4). The majority of studies have proposed that ZWINT acts as a structural protein, which is part of the inner kinetochore scaffold and recruits zeste white 10, which is also a centromere protein, to the kinetochore (5,6). Upregulation of ZWINT has been observed in numerous types of cancer, including ovarian and hepatocellular cancer, as well as glioblastoma, and is indicative of a worse prognosis (79). ZWINT depletion has been demonstrated to attenuate cell proliferation in 293-T and BC MCF-7 cells via Terf/tripartite motif containing 17 (TRIM17) signaling (10). In addition, abnormal expression of ZWINT has been reported to be associated with chromosomal instability and poor clinical outcomes in certain types of cancer (11). Furthermore, downregulated expression of ZWINT, mediated by the inhibition of cyclooxygenase-2, has been reported to impede the proliferation of prostate cancer cells via prostaglandin E receptor-1 signaling (12). These results suggested that ZWINT may serve an essential role in cancer progression and development.

Since the expression and clinical implication of ZWINT have not been comprehensively investigated in human BC, the current study examined the significance of ZWINT expression in human BC via bioinformatics analysis. The aim of the present study was to evaluate the expression profile, roles and accuracy of ZWINT as a biomarker for the long-term prognostic prediction of BC through pooling and analyzing currently available data.

Materials and methods

Tissue specimens and immunohistochemistry (IHC)

BC and adjacent normal breast tissue specimens were collected from 62 patients who had been treated at the Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology (Wuhan, China) between September 2016 and June 2018. The patients that participated in the study had not received chemotherapy, radiotherapy, targeted therapy or other treatment prior to surgery. All patients in this study were women and were aged between 28 and 77 years (median age, 47 years). Written informed consent was obtained from all patients and the experimental protocol was approved by the Ethics Committee of Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology. The collected specimens were immediately fixed with 10% neutral formaldehyde for 12 h at room temperature. The fixed specimens were paraffin-embedded and cut into 4 µm thick sections. IHC was conducted using Polink-2 plus® Polymer HRP Detection system (cat. no. PV-0023; BIOSS) according to the manufacturer's instructions. Sections were incubated with the primary antibody against ZWINT (cat. no. bs-7852R; BIOSS;1:200) at 4°C overnight, and with horseradish peroxidase-conjugated anti-rabbit immunoglobulin G (cat.no. bs-0295D-HRP; BIOSS; 1:500) at 37°C for 20 min. The specimens were examined using an Olympus BX-51 microscope (Olympus, Corporation; magnification, ×200) by two experienced pathologists. Results were scored according to the staining intensity and the percentage of positive cells on a 3- and 4-point scale. Staining intensity was graded as follows: 0, negative; 1, weak; 2, moderate; or 3, strong. The ratio of stained positive cells was scored as follows: 0, no staining; 1, ≤25%; 2, 26–50%; 3, 51–75%; and 4, >75%. The total score was calculated as the sum of the intensity and percentage scores. Additionally, for semi-quantitative analysis, a score ≤4 was considered to indicate low ZWINT expression and a score >4 high ZWINT expression.

Gene Expression Profiling Interactive Analysis (GEPIA)-based cancer data analysis

GEPIA (http://gepia.cancer-pku.cn/) analysis based on The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression, which contains a large number of RNA sequencing data for cancer and normal tissues, was conducted to examine the mRNA expression levels of ZWINT in BC and adjacent normal tissues (13).

Oncomine database analysis

Data regarding the transcription levels of ZWINT in BC were retrieved from the Oncomine database (https://www.oncomine.org/), a cancer research database that contains a large number of datasets and samples, on the basis of microarray and high-throughput sequencing. A fold change >2, P<1×10−4 and genes ranking in the top 10%, with simultaneous data restricted to mRNA were set as significance cut-off levels. Four datasets [TCGA Breast (14), Curtis Breast (15), Ma Breast (16) and Richardson Breast (17)] were used to analyze the differential expression of ZWINT in multiple pathological types of BC and normal breast tissue.

Expression levels of ZWINT and clinical outcomes of BC

mRNA expression of ZWINT in different types of molecular and clinicopathological BC, and its association with prognosis were evaluated by employing Breast Cancer Gene-Expression Miner (version 4.1; bc-GenExMiner) which is a mining tool and a web source of published BC genomic data (18,19). A P-value indicating statistically significant differences among groups (age, nodal status, ER, PR, Her-2, SBR grade, triple negative status and basal-like status) was generated using Welch's test followed by the Dunnett-Tukey-Kramer's test. Moreover, Kaplan-Meier Plotter (https://kmplot.com/), which is an online database that contains data from 5,143 patients with BC, 2,437 patients with lung cancer, 1,816 patients with ovarian cancer, 1,065 patients with gastric cancer and 364 patients with liver cancer combined with relapse-free survival (RFS) and overall survival (OS) data (20), was used to assess the relationship between the transcription levels of ZWINT and OS or RFS among patients with BC. Specifically, clinical samples were divided into high expression and low expression groups in terms of the median expression value of ZWINT. Subsequently, the log rank P-value and hazard ratio (HR) with 95% confidence interval (CI) were calculated. In addition, the impact of ZWINT on metastatic relapse-free survival (MRFS) and the risk of metastatic relapse (MR) of BC patients were evaluated in all cohorts in bc-GenExMiner pooled by means of univariate Cox regression model, and were illustrated with a Kaplan-Meier curve and a forest plot, respectively.

Mutation and copy number variation (CNV) analysis of ZWINT

Mutations of ZWINT were evaluated using the Catalogue of Somatic Mutations in Cancer (COSMIC) database, which is a comprehensive resource of somatic mutations identified in numerous types of human cancer (21,22). The distribution of various mutations was included and presented in the form of a pie chart. In addition, the cBio Cancer Genomics Portal (cBioPortal) (http://cbioportal.org) database was used to examine the alteration frequency of ZWINT mutations and CNVs in BC (23,24). The following data were used in cBioPortal: i) Breast Cancer [MSK, Cancer Cell 2018 (25)] ii) Breast Cancer [METABRIC (26)] iii): Breast [BCCRC 2012 (27)] iv): Breast [Broad 2012 (28)] v): Breast [Sanger (29)] vi) Breast [TCGA (30)] vii): Breast [BCCRC Xenograft (31)]; viii) BRCA [INSERM 2016 (32)].

Gene set enrichment analysis (GSEA)

The functional role of ZWINT was determined by performing GSEA. GSEA acts as a computational tool to evaluate whether a pre-defined set of genes demonstrates statistically significant, consistent differences between two biological states, including phenotypes (33). In the present study, the original mRNA sequencing data of BC were downloaded from TCGA and the samples were sorted in terms of ZWINT expression levels. A hundred samples were divided into high or low categories (50 samples in each category) based on the ZWINT expression levels, in order to annotate phenotype and the ‘Hallmarks’ gene set from the Molecular Signatures Database (MSigDB h.all.v6.2.symbols.gmt) was used for enrichment analysis. False discovery rate <0.25 and nominal P-value <0.05 were set as cut-off criteria.

Co-expression and correlation analysis

The ‘coexpression analysis’ module of Oncomine database was used to investigate the co-expressed genes of ZWINT in BC. The feature of ‘gene correlation analysis’ of the cBioPortal and bc-GenExMiner was used to verify the co-expression of ZWINT and CDK1 in BC, and linear (Pearson) and/or nonparametric (Spearman) correlation coefficients were calculated to assess the correlation intensity between these two genes. P<0.05 was considered to be statistically significant.

Statistical analysis

IHC data were analyzed using SPSS software (version 21.0; IBM Corp.). A Wilcoxon matched-pairs signed rank test was conducted to compare BC tissues and adjacent normal tissues, and data are presented as the median ± interquartile range. Fisher's exact test was used to analyze the association between ZWINT expression and clinicopathological characteristics. Moreover, data from the bc-GenExMiner database were used to analyze the mRNA expression of ZWINT in terms of clinicopathological characteristics with Welch's test and the Dunnett-Tukey-Kramer's test. The MRFS and MR of BC patients were estimated by the univariate Cox regression. P<0.05 was considered to indicate a statistically significant difference.

Results

ZWINT expression in human BC. The mRNA expression profile of ZWINT in BC was studied by searching GEPIA and the Oncomine database. Elevated ZWINT expression was identified in BC tissues compared with normal tissues (Fig. 1A). Furthermore, the results demonstrated that ZWINT mRNA was significantly overexpressed in mucinous, medullary, invasive lobular and invasive ductal breast carcinoma compared with the normal breast tissues (Table I). In addition, IHC analysis confirmed that ZWINT expression was higher in BC tissues compared with adjacent normal breast tissues (Fig. 1B-D).

Table I.

ZW10 interacting kinetochore protein expression in different subtypes of breast carcinoma.

Table I.

ZW10 interacting kinetochore protein expression in different subtypes of breast carcinoma.

SubtypeCancerNormalP-valueFold changeRank (%)Source of raw data (ref)
Invasive Breast Carcinoma7661 3.19×10−355.1331
Invasive Lobular Breast Carcinoma3661 1.47×10−184.3731TCGA (14)
Invasive Ductal Breast Carcinoma38961 2.73×10−445.9891
Invasive Ductal Breast Carcinoma1556144 3.04×10−1212.8091
Invasive Breast Carcinoma21144 1.09×10−82.3131
Invasive Lobular Breast Carcinoma148144 3.80×10−492.2531
Invasive Ductal and Invasive Lobular90144 4.24×10−352.5641Curtis et al (15)
Breast Carcinoma
Medullary Breast Carcinoma32144 5.66×10−152.7891
Mucinous Breast Carcinoma46144 3.96×10−172.2082
Breast Carcinoma14144 8.10×10−62.5473
Tubular Breast Carcinoma67144 2.45×10−232.0873
Invasive Ductal Breast Carcinoma914 6.50×10−53.5532Ma et al (16)
Ductal Breast Carcinoma In Situ914 3.74×10−53.7872
Ductal Breast Carcinoma407 9.56×10−67.5936Richardson et al (17)
ZWINT mutations in human BC

COSMIC database analysis identified two types of ZWINT mutations in BC, missense and synonymous substitutions (Fig. 2A). For substitution mutations, the data revealed that C>A and G>A mutations accounted for 25 and 75% of the ZWINT coding strand, respectively (Fig. 2B). cBioPortal was applied to assess the genomic alteration frequency of ZWINT in BC and the results revealed that ZWINT genomic alteration exceeded 5%, including amplification, mutation and deep deletion (Fig. 2C). A total of three locations of ZWINT mutation, including E18K, A117S and A151E, were found in cBioPortal database (Fig. 2D).

Association between ZWINT expression and different clinicopathological indicators

In bc-GenExMiner, the mRNA expression of ZWINT among groups of patients with different clinicopathological parameters was assessed using Welch's test followed by the Dunnett-Tukey-Kramer's test. The mRNA expression levels of ZWINT were significantly increased in patients aged 24–40, compared with those aged 41–69 (P<0.0001) and 70–93 (P<0.01). Nevertheless, no statistical difference was observed between patients aged 41–69 and aged 70–93 (P>0.1; Fig. 3A). Additionally, no significant differences were found between patients with positive nodal status and those with negative status (P=0.7048; Table II). Furthermore, in terms of classical molecular types of BC, patients with estrogen receptor (ER) or progesterone receptor (PR) (P<0.0001 for both) and human epidermal growth factor receptor 2 (HER2)+ (P=0.0216) status had higher ZWINT expression levels than their respective opposite status (Table II). Triple-negative BC (TNBC), an aggressive type of BC, has been identified to lack expression of PR, ER and HER2 (34). The expression of ZWINT was found to be significantly upregulated in patients with TNBC (P<0.0001; Table II). Additionally, patients with basal-like features had significantly increased ZWINT expression compared with patients without basal-like traits (P<0.0001; Table II). Moreover, in terms of Scarff Bloom and Richardson (SBR) grades, patients with a more advanced SBR grade exhibited higher ZWINT expression (SBR3 > SBR1, P<0.0001; SBR2 > SBR1, P<0.0001; SBR3 > SBR2, P<0.0001; Fig. 3B). In addition to these results, IHC indicated significant differences in the protein expression of ZWINT between various age groups, PR and HER2 expression groups, and TNBC status groups (all P<0.05), whereas there was no statistically significant difference between groups with different node status or ER expression status (both P>0.05; Table III).

Table II.

Clinicopathological characteristics and the mRNA expression levels of ZWINT in patients with BC according to the bc-GenExMiner analysis.a

Table II.

Clinicopathological characteristics and the mRNA expression levels of ZWINT in patients with BC according to the bc-GenExMiner analysis.a

VariablesNumbermRNA expressionP-value
Nodal status 0.7048
  Negative2426
  Positive1480
ER (IHC) <0.0001
  Negative1388Increased
  Positive3675
PR (IHC) <0.0001
  Negative804Increased
  Positive1249
HER2 (IHC) 0.0216
  Negative1409
  Positive201Increased
Triple-negative status <0.0001
  No3831
  Yes374Increased
Basal-like status <0.0001
  None-basal-like3904
  Basal-like1048Increased

a ZWINT mRNA expression data are derived from bc-GenExMiner and the P-value is from Welch's test, which was followed by the Dunnett-Tukey-Kramer's test. bc-GenExMiner, Breast Cancer Gene-Expression Miner; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; N, nodal status; PR, progesterone receptor; ZWINT, ZW10 interacting kinetochore protein.

Table III.

ZWINT expression in subgroups as detected by immunohistochemistry.

Table III.

ZWINT expression in subgroups as detected by immunohistochemistry.

ZWINT expression

VariablesNumber (n=62)LowHighP-value
Age (years) 0.0063
  ≤4038830
  >40241410
Nodal status 0.2884
  Negative371126
  Positive251114
ER 0.2891
  Negative32923
  Positive301317
PR 0.0008
  Negative38731
  Positive24159
HER2 0.0277
  Negative401030
  Positive221210
Triple-negative status 0.0018
  No442024
  Yes18216

[i] ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; N, nodal status; PR, progesterone receptor; ZWINT, ZW10 interacting kinetochore protein.

ZWINT expression and the prognosis of patients with BC

According to Kaplan-Meier Plotter analysis, higher ZWINT expression was associated with a shorter OS (HR=1.73; 95% CI=1.39–2.15; P=5.4×10−7) and a shorter RFS (HR=1.68; 95% CI=1.51–1.88; P<1×10−16) (Fig. 4). Gene prognostic analysis was conducted with bc-GenExMiner, which involved the integration of the accessible annotated genomic resources in order to explore the association between ZWINT expression and metastatic relapse-free survival (MRFS). As presented in Fig. 5A, increased ZWINT expression levels were related to shorter MRFS (HR=1.66; 95% CI=1.46–1.89; P<0.0001). Moreover, a higher risk of metastatic relapse was observed in patients with elevated ZWINT expression (HR=1.34; 95% CI=1.26–1.43; P<0.0001; Fig. 5B).

Molecular mechanisms and co-expression of ZWINT in BC

Increased ZWINT expression was found to be related to worse prognosis in patients with BC. Nonetheless, the underlying molecular mechanisms remain to be explored. In order to evaluate whether the expression levels of ZWINT were related to known gene signatures, GSEA was performed with BC RNA-sequencing data from TCGA database. GSEA revealed that 11 hallmark pathways were upregulated in the high ZWINT expression group, indicating that ZWINT expression was positively associated with these pathways (Table IV). Most of these pathways are implicated in cellular metabolism, biosynthesis and cell damage repair processes, including Myc targets V1/2, DNA repair, mitotic spindle, G2M checkpoint and E2F targets (Fig. 6). In addition, co-expression analysis was performed using the Oncomine database to further study the regulation of ZWINT. In total, 124 co-expression genes were filtered out in a cohort of 289 patients with BC (Fig. 7A) (35). The gene with the greatest correlation score, cyclin-dependent kinase 1 (CDK1), is considered to serve an important role in the regulation of the cell cycle process and has been confirmed to be abnormally upregulated in several types of cancer by numerous studies (3640). A positive correlation was confirmed between ZWINT and CDK1 mRNA expression in the METABRIC database by employing cBioPortal (Spearman's correlation=0.80; Pearson's correlation=0.79; Fig. 7B). Data mining in bc-GenExMiner further verified the positive correlation between ZWINT and CDK1 mRNA expression (Fig. 7C). These results indicated that ZWINT could be involved in biosynthesis, cell cycle and damage repair processes, and may be related to CDK1 signaling pathways.

Table IV.

Association between ZW10 interacting kinetochore protein expression and predefined gene signatures, as determined by Gene Set Enrichment Analysis.

Table IV.

Association between ZW10 interacting kinetochore protein expression and predefined gene signatures, as determined by Gene Set Enrichment Analysis.

NameSizeESNESNOM P-valueFDR q-value
HALLMARK_MYC_TARGETS_V11980.7406072.0176100.007663
HALLMARK_DNA_REPAIR1400.555832.00127200.004239
HALLMARK_MITOTIC_SPINDLE1980.6163441.9835900.003048
HALLMARK_MTORC1_SIGNALING1960.634021.9687460.0019570.003571
HALLMARK_MYC_TARGETS_V2580.7552161.921420.0019650.005123
HALLMARK_UNFOLDED_PROTEIN_RESPONSE1080.4926821.8886220.0096530.00677
HALLMARK_SPERMATOGENESIS730.6071111.7911630.008130.015301
HALLMARK_G2M_CHECKPOINT1960.8224511.77404600.016042
HALLMARK_E2F_TARGETS1990.8655911.76309700.01676
HALLMARK_OXIDATIVE_PHOSPHORYLATION1980.5502281.7484840.0527310.017751
HALLMARK_GLYCOLYSIS1810.4303541.5446760.0406190.083129

[i] ES, enrichment score; FDR, false discovery rate; NES, normalized enrichment score; NOM, nominal.

Discussion

Previous studies have examined the expression and roles of ZWINT in multiple types of cancer (79,11,12). Endo et al (10) demonstrated that the interaction of ZWINT with Terf/TRIM17 resulted in its degradation and the consequent regulation of cell proliferation in BC MCF-7 and 293-T cells. Miller et al (41) identified a total of 62 genes, including ZWINT, whose expression levels were markedly changed in BC after short-term therapy with letrozole, indicating that ZWINT was potentially involved in estrogen regulation. However, the expression profile of ZWINT and its effect on BC prognosis remain unexplored.

In the present study, the expression profile of ZWINT in BC was initially evaluated by IHC and GEPIA. Βoth the mRNA and protein expression levels of ZWINT were found to be elevated in BC tissues, suggesting that it may serve an oncogenic role in BC. The Oncomine database search revealed that the transcriptional expression of ZWINT was significantly upregulated in mucinous, medullary, invasive lobular and invasive ductal breast carcinoma. Furthermore, increased ZWINT expression was found to be significantly associated with HER2 positivity, a basal-like subtype of breast carcinoma, TNBC and increased histological grades according to SBR grading. Moreover, significant associations were observed between increased ZWINT mRNA expression and negative expression of ER/PR as well as younger age of the patients. Previous studies have demonstrated that BC in young women (BCYW) has distinctive clinicopathological characteristics compared with BC in post-menopausal women (42,43). Specifically, BCYW is often of a higher grade, is more aggressive, lacks endocrine receptor expression and has a higher proportion of HER2+ and triple-negative histology (4446). The present study demonstrated that ZWINT mRNA expression was higher in BCYW than in BC in older patients, suggesting that ZWINT may serve an important role in the progression of BC, particularly in BCYW. Furthermore, IHC detection revealed a close association between ZWINT expression and the age of patients, PR and HER2 status, and TNBC in BC. Nevertheless, the results were partly in disagreement with the findings of the bc-GenExMiner. For instance, no association was found between ZWINT expression and ER status in the study cohort, which may be due to the relatively small sample size, and ethnic or geographical differences. Kaplan Meier-plotter analysis revealed that high ZWINT expression was related to unfavorable OS and RFS. Additionally, data mining with bc-GenExMiner demonstrated that high ZWINT expression was strongly associated with increased risk of metastatic relapse. These findings suggested that ZWINT may serve as a biomarker for the prognosis of BC.

To explore the role of ZWINT in BC, GSEA was performed. This analysis demonstrated that higher expression of ZWINT was closely associated with cell cycle-related pathways, including Myc targets V1/2, DNA repair, mitotic spindle, G2M checkpoint and E2F targets. It is generally believed that aberrant cellular proliferation is a hallmark of malignancies and tumor cells tend to exhibit altered expression of genes that directly modulate their cell cycle (47). This process occurs either via mutations in the upstream signaling pathways or as a consequence of genetic impairments in genes encoding cell cycle-related proteins (48). As a proto-oncogene, Myc encodes a nuclear phosphoprotein and is involved in cell cycle progression, apoptosis and cellular transformation (49). Myc is rigorously controlled in normal cells, whereas it is aberrantly expressed in the majority of types of human cancer (50). Notably, the internal interaction between Myc and the E2F family of transcription factors in BC has been reported by several studies. For instance, Fujiwara et al (51) generated a hybrid mouse model and demonstrated that Myc-induced breast tumor latency was significantly decreased in E2F1 knockout mice and increased in E2F2 and E2F3 knockout mice. A follow-up study, however, revealed that lack of E2F1 or E2F3 significantly postponed tumor onset in both ErbB2- and Myc-triggered breast tumorigenesis, whereas lack of E2F2 promoted breast tumorigenesis induced by Myc overexpression (52). The present results demonstrated that in addition to recognized involvement in the mitotic spindle checkpoint, ZWINT may participate in the signaling pathways of Myc and E2F in BC. Nevertheless, given the complexity of the cell cycle, the precise role of ZWINT in BC could not be determined. To further investigate the molecular mechanism of ZWINT in BC, co-expression and correlation analyses were performed. It was demonstrated that ZWINT may be closely associated with the CDK1 signaling pathways in BC. Importantly, CDK1 has been observed to serve an essential role in tumor initiation and progression in different types of carcinomas (40,53,54). Ablation of the CDK1 gene induced resistance to NRAS-G12V-induced tumorigenesis in liver cells (55). Moreover, CDK1 inhibition in combination with mitogen-activated protein kinase kinase inhibition synergistically increased the apoptotic rate of colorectal cancer cells and decreased clonogenic survival as compared with monotreatment (56). These results suggested that ZWINT may promote tumor formation and progression by modulating CDK1 expression in BC. Further studies are warranted to determine the relationship between ZWINT and CDK1 in BC.

In summary, the present study identified that ZWINT was commonly upregulated in BC and may aid prognostic prediction in patients with BC. ZWINT may serve as an independent prognostic biomarker for BC; however, further research is required to substantiate the findings of the present study.

Acknowledgments

Not applicable.

Funding

This project was supported by the Hubei Provincial Natural Science Foundation of China (grant no. 2015000250) and the Clinical Research Physician Program of Tongji Medical College, HUST (grant no. 2017zqnlxr01).

Availability of data and materials

All data generated or analyzed during the present study are included in this published article.

Authors' contributions

HL was completed the bioinformatic research and was a major contributor of manuscript preparation. WZ designed the project and made the study plan. YD was responsible for the analysis of the clinical characteristics of breast cancer specimens. GW and MD performed the immunohistochemistry and analyzed the results. ZY and XL contributed to the writing and revision of the manuscript, and provided valuable input on the design of the experiment and the interpretation of the results. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

The experimental protocol of the present study was approved by the Ethics Committee of Tongji Hospital. Written informed consent was obtained from all patients.

Patient consent for publication

The experimental protocol of this study was approved by the Ethics Committee of Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology. All patients provided signed informed consent.

Competing interests

The authors declare that they have no competing interests.

References

1 

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI

2 

Greenlee H, DuPont-Reyes MJ, Balneaves LG, Carlson LE, Cohen MR, Deng G, Johnson JA, Mumber M, Seely D, Zick SM, et al: Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 67:194–232. 2017. View Article : Google Scholar : PubMed/NCBI

3 

Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, et al: American cancer society/American society of clinical oncology breast cancer survivorship care guideline. J Clin Oncol. 34:611–635. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Starr DA, Saffery R, Li Z, Simpson AE, Choo KH, Yen TJ and Goldberg ML: HZwint-1, a novel human kinetochore component that interacts with HZW10. J Cell Sci. 113:1939–1950. 2000.PubMed/NCBI

5 

Vos LJ, Famulski JK and Chan GK: hZwint-1 bridges the inner and outer kinetochore: Identification of the kinetochore localization domain and the hZw10-interaction domain. Biochem J. 436:157–168. 2011. View Article : Google Scholar : PubMed/NCBI

6 

Kops GJ, Kim Y, Weaver BA, Mao Y, McLeod I, Yates JR III, Tagaya M and Cleveland DW: ZW10 links mitotic checkpoint signaling to the structural kinetochore. J Cell Biol. 169:49–60. 2005. View Article : Google Scholar : PubMed/NCBI

7 

Tang J, He D, Yang P, He J and Zhang Y: Genome-wide expression profiling of glioblastoma using a large combined cohort. Sci Rep. 8:151042018. View Article : Google Scholar : PubMed/NCBI

8 

Xu Z, Zhou Y, Cao Y, Dinh TL, Wan J and Zhao M: Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis. Med Oncol. 33:1302016. View Article : Google Scholar : PubMed/NCBI

9 

Ying H, Xu Z, Chen M, Zhou S, Liang X and Cai X: Overexpression of Zwint predicts poor prognosis and promotes the proliferation of hepatocellular carcinoma by regulating cell-cycle-related proteins. Onco Targets Ther. 11:689–702. 2018. View Article : Google Scholar : PubMed/NCBI

10 

Endo H, Ikeda K, Urano T, Horie-Inoue K and Inoue S: Terf/TRIM17 stimulates degradation of kinetochore protein ZWINT and regulates cell proliferation. J Biochem. 151:139–144. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Pérez de Castro I, de Cárcer G and Malumbres M: A census of mitotic cancer genes: New insights into tumor cell biology and cancer therapy. Carcinogenesis. 28:899–912. 2007. View Article : Google Scholar : PubMed/NCBI

12 

Bieniek J, Childress C, Swatski MD and Yang W: COX-2 inhibitors arrest prostate cancer cell cycle progression by down-regulation of kinetochore/centromere proteins. Prostate. 74:999–1011. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI

14 

Cancer Genome Atlas Network, . Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI

15 

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 486:346–352. 2012. View Article : Google Scholar : PubMed/NCBI

16 

Ma XJ, Dahiya S, Richardson E, Erlander M and Sgroi DC: Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 11:R72009. View Article : Google Scholar : PubMed/NCBI

17 

Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM and Ganesan S: X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 9:121–132. 2006. View Article : Google Scholar : PubMed/NCBI

18 

Jézéquel P, Campone M, Gouraud W, Guérin-Charbonnel C, Leux C, Ricolleau G and Campion L: bc-GenExMiner: An easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat. 131:765–775. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Jézéquel P, Frénel JS, Campion L, Guérin-Charbonnel C, Gouraud W, Ricolleau G and Campone M: bc-GenExMiner 3.0: New mining module computes breast cancer gene expression correlation analyses. Database (Oxford). 2013:bas0602013. View Article : Google Scholar : PubMed/NCBI

20 

Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI

21 

Forbes SA, Beare D, Bindal N, Bamford S, Ward S, Cole CG, Jia M, Kok C, Boutselakis H, De T, et al: COSMIC: High-resolution cancer genetics using the catalogue of somatic mutations in cancer. Curr Protoc Hum Genet. 91:10.11.1–10.11.37. 2016. View Article : Google Scholar

22 

Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L, et al: COSMIC: Somatic cancer genetics at high-resolution. Nucleic Acids Res. 45:D777–D783. 2017. View Article : Google Scholar : PubMed/NCBI

23 

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI

24 

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI

25 

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, et al: The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 34:427.e6–438.e6. 2018. View Article : Google Scholar

26 

Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, et al: The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 7:114792016. View Article : Google Scholar : PubMed/NCBI

27 

Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al: The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 486:395–399. 2012. View Article : Google Scholar : PubMed/NCBI

28 

Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, et al: Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 486:405–409. 2012. View Article : Google Scholar : PubMed/NCBI

29 

Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, et al: The landscape of cancer genes and mutational processes in breast cancer. Nature. 486:400–404. 2012. View Article : Google Scholar : PubMed/NCBI

30 

Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et al: Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 163:506–519. 2015. View Article : Google Scholar : PubMed/NCBI

31 

Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, Gelmon K, Chia S, Mar C, Wan A, et al: Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature. 518:422–426. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria JC, Massard C, Lévy C, Arnedos M, Lacroix-Triki M, et al: Mutational profile of metastatic breast cancers: A retrospective analysis. PLoS Med. 13:e10022012016. View Article : Google Scholar : PubMed/NCBI

33 

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI

34 

Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI

35 

Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, et al: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 66:10292–10301. 2006. View Article : Google Scholar : PubMed/NCBI

36 

Malumbres M: Cyclin-dependent kinases. Genome Biol. 15:1222014. View Article : Google Scholar : PubMed/NCBI

37 

Ravindran Menon D, Luo Y, Arcaroli JJ, Liu S, KrishnanKutty LN, Osborne DG, Li Y, Samson JM, Bagby S, Tan AC, et al: CDK1 interacts with Sox2 and promotes tumor initiation in human melanoma. Cancer Res. 78:6561–6574. 2018. View Article : Google Scholar : PubMed/NCBI

38 

Wei D, Parsels LA, Karnak D, Davis MA, Parsels JD, Marsh AC, Zhao L, Maybaum J, Lawrence TS, Sun Y and Morgan MA: Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair. Clin Cancer Res. 19:4422–4432. 2013. View Article : Google Scholar : PubMed/NCBI

39 

Whalley HJ, Porter AP, Diamantopoulou Z, White GR, Castañeda-Saucedo E and Malliri A: Cdk1 phosphorylates the Rac activator Tiam1 to activate centrosomal Pak and promote mitotic spindle formation. Nat Commun. 6:74372015. View Article : Google Scholar : PubMed/NCBI

40 

Wu CX, Wang XQ, Chok SH, Man K, Tsang SHY, Chan ACY, Ma KW, Xia W and Cheung TT: Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. Theranostics. 8:3737–3750. 2018. View Article : Google Scholar : PubMed/NCBI

41 

Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, Murray E, Hampton G, Walker JR, Ho S, et al: Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics. 17:813–826. 2007. View Article : Google Scholar : PubMed/NCBI

42 

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Veronesi P, Torrisi R, Montagna E, Luini A, et al: Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol. 21:1974–1981. 2010. View Article : Google Scholar : PubMed/NCBI

43 

Narod SA: Breast cancer in young women. Nat Rev Clin Oncol. 9:460–470. 2012. View Article : Google Scholar : PubMed/NCBI

44 

Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C and Loi S: Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 18:1341–1351. 2012. View Article : Google Scholar : PubMed/NCBI

45 

Han W and Kang SY; Korean Breast Cancer Society, : Relationship between age at diagnosis and outcome of premenopausal breast cancer: Age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat. 119:193–200. 2010. View Article : Google Scholar : PubMed/NCBI

46 

Keegan TH, DeRouen MC, Press DJ, Kurian AW and Clarke CA: Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res. 14:R552012. View Article : Google Scholar : PubMed/NCBI

47 

Sherr CJ: Cancer cell cycles. Science. 274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI

48 

Otto T and Sicinski P: Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 17:93–115. 2017. View Article : Google Scholar : PubMed/NCBI

49 

Bretones G, Delgado MD and León J: Myc and cell cycle control. Biochim Biophys Acta. 1849:506–516. 2015. View Article : Google Scholar : PubMed/NCBI

50 

Wahlström T and Henriksson MA: Impact of MYC in regulation of tumor cell metabolism. Biochim Biophys Acta. 1849:563–569. 2015. View Article : Google Scholar : PubMed/NCBI

51 

Fujiwara K, Yuwanita I, Hollern DP and Andrechek ER: Prediction and genetic demonstration of a role for activator E2Fs in Myc-induced tumors. Cancer Res. 71:1924–1932. 2011. View Article : Google Scholar : PubMed/NCBI

52 

Wu L, de Bruin A, Wang H, Simmons T, Cleghorn W, Goldenberg LE, Sites E, Sandy A, Trimboli A, Fernandez SA, et al: Selective roles of E2Fs for ErbB2- and Myc-mediated mammary tumorigenesis. Oncogene. 34:119–128. 2015. View Article : Google Scholar : PubMed/NCBI

53 

Liu X, Gao Y, Ye H, Gerrin S, Ma F, Wu Y, Zhang T, Russo J, Cai C, Yuan X, et al: Positive feedback loop mediated by protein phosphatase 1α mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic Acids Res. 45:3738–3751. 2017.PubMed/NCBI

54 

Saatci Ö, Borgoni S, Akbulut Ö, Durmuş S, Raza U, Eyüpoğlu E, Alkan C, Akyol A, Kütük Ö, Wiemann S and Şahin Ö: Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer. Oncogene. 37:2251–2269. 2018. View Article : Google Scholar : PubMed/NCBI

55 

Diril MK, Ratnacaram CK, Padmakumar VC, Du T, Wasser M, Coppola V, Tessarollo L and Kaldis P: Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration. Proc Natl Acad Sci USA. 109:3826–3831. 2012. View Article : Google Scholar : PubMed/NCBI

56 

Zhang P, Kawakami H, Liu W, Zeng X, Strebhardt K, Tao K, Huang S and Sinicrope FA: Targeting CDK1 and MEK/ERK overcomes apoptotic resistance in BRAF-mutant human colorectal cancer. Mol Cancer Res. 16:378–389. 2018. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

March-2020
Volume 19 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li HN, Zheng WH, Du YY, Wang G, Dong ML, Yang ZF and Li XR: ZW10 interacting kinetochore protein may serve as a prognostic biomarker for human breast cancer: An integrated bioinformatics analysis. Oncol Lett 19: 2163-2174, 2020
APA
Li, H., Zheng, W., Du, Y., Wang, G., Dong, M., Yang, Z., & Li, X. (2020). ZW10 interacting kinetochore protein may serve as a prognostic biomarker for human breast cancer: An integrated bioinformatics analysis. Oncology Letters, 19, 2163-2174. https://doi.org/10.3892/ol.2020.11353
MLA
Li, H., Zheng, W., Du, Y., Wang, G., Dong, M., Yang, Z., Li, X."ZW10 interacting kinetochore protein may serve as a prognostic biomarker for human breast cancer: An integrated bioinformatics analysis". Oncology Letters 19.3 (2020): 2163-2174.
Chicago
Li, H., Zheng, W., Du, Y., Wang, G., Dong, M., Yang, Z., Li, X."ZW10 interacting kinetochore protein may serve as a prognostic biomarker for human breast cancer: An integrated bioinformatics analysis". Oncology Letters 19, no. 3 (2020): 2163-2174. https://doi.org/10.3892/ol.2020.11353